Although several biological agents, such as tumour necrosis factor α (TNFα) blockers, display potent efficacy in alleviating RA symptoms, a considerable percentage of anti-TNFα-treated patients do not show a significant clinical response2,3. The gene discussed is TNF; the disease is rheumatoid arthritis.